ReviewJournal of Cancer2018
The emergence of long non-coding RNAs in hepatocellular carcinoma: an update.
Review in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Diagnostic Value of lncRNAs as Biomarker in Hepatocellular Carcinoma: An Updated Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2018Pooled it
- Genetic Variants in EMT-Related lncRNAs Modulate the Risk of Colorectal Cancer in the Chinese Population.Biochemical genetics · 2026Article
- LincRNA-miR interactions in hepatocellular carcinoma: comprehensive review and in silico analysis: a step toward ncRNA precision.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Diagnosis of the Initial Stage of Hepatocellular Carcinoma: A Review.Current pharmaceutical design · 2024Review
- Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1α/METTL16/lnc-CSMD1-7/RBFOX2 axis.iScience · 2023Article
- Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials.Bioengineering (Basel, Switzerland) · 2022Review
- Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.World journal of gastroenterology · 2022Review
- Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications.Journal of cancer research and clinical oncology · 2022Review
- Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.Frontiers in immunology · 2022Review
- The identification and preliminary study of lncRNA TUG1 and its related genes in hepatocellular carcinoma.Archives of medical science : AMS · 2022Article
- Long non‑coding RNA ZSCAN16‑AS1 promotes the malignant properties of hepatocellular carcinoma by decoying microRNA‑451a and consequently increasing ATF2 expression.Molecular medicine reports · 2021Article
- Article
- Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- linc00174-EZH2-ZNF24/Runx1-VEGFA Regulatory Mechanism Modulates Post-burn Wound Healing.Molecular therapy. Nucleic acids · 2020Article
- Advances in the early diagnosis of hepatocellular carcinoma.Genes & diseases · 2020Review
- LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma.International journal of molecular sciences · 2020Review
- Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.BioMed research international · 2020Review
- Role of microRNA and Long Non-Coding RNA in Hepatocellular Carcinoma.Current pharmaceutical design · 2020Review
- The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) accounting for roughly 90% of all primary liver neoplasms is the sixth most frequent neoplasm and the second prominent reason of tumor fatality worldwide. As regulators of diverse biological processes, long non-coding RNAs (lncRNAs) are involved in onset and development of neoplasms. With the continuous booming of well-featured lncRNAs in HCC from 2016 to now, we reviewed the newly-presented comprehension about the relationship between lncRNAs and HCC in this study. To be specific, we summarized the overview function and study tools of lncRNAs, elaborated the roles of lncRNAs in HCC, and sketched the molecule mechanisms of lncRNAs in HCC. In addition, the application of lncRNAs serving as biomarkers in early diagnosis and outcome prediction of HCC patients was highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.